Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21

The cisplatin analogue 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) (DAP) is a DNA-damaging agent that will be entering clinical trials for its potent cytotoxic effects against cisplatin-resistant tumour cells. This cytotoxicity may reside in its ability to selectively activate G1...

Descripción completa

Detalles Bibliográficos
Autores principales: He, G, Kuang, J, Huang, Z, Koomen, J, Kobayashi, R, Khokhar, A R, Siddik, Z H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360737/
https://www.ncbi.nlm.nih.gov/pubmed/17088910
http://dx.doi.org/10.1038/sj.bjc.6603448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360737/
https://www.ncbi.nlm.nih.gov/pubmed/17088910
http://dx.doi.org/10.1038/sj.bjc.6603448

Ejemplares similares